ID: ALA4077342

Max Phase: Preclinical

Molecular Formula: C24H21Cl3F2NO6PS

Molecular Weight: 626.83

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=P(O)(O)C(F)(c1ccc(-c2cccc(Cc3cc(Cl)c(Cl)cc3Cl)c2F)cc1)S(=O)(=O)N1CCOCC1

Standard InChI:  InChI=1S/C24H21Cl3F2NO6PS/c25-20-14-22(27)21(26)13-17(20)12-16-2-1-3-19(23(16)28)15-4-6-18(7-5-15)24(29,37(31,32)33)38(34,35)30-8-10-36-11-9-30/h1-7,13-14H,8-12H2,(H2,31,32,33)

Standard InChI Key:  WGLNSQXDSIOHHO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 626.83

Molecular Weight (Monoisotopic): 624.9861

AlogP: 5.96

#Rotatable Bonds: 7

Polar Surface Area: 104.14

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 0.72

CX Basic pKa:

CX LogP: 6.05

CX LogD: 3.41

Aromatic Rings: 3

Heavy Atoms: 38

QED Weighted: 0.25

Np Likeness Score: -0.78

References

1. Witten MR, Wissler L, Snow M, Geschwindner S, Read JA, Brandon NJ, Nairn AC, Lombroso PJ, Käck H, Ellman JA..  (2017)  X-ray Characterization and Structure-Based Optimization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors.,  60  (22): [PMID:29116812] [10.1021/acs.jmedchem.7b01292]

2. Witten MR, Wissler L, Snow M, Geschwindner S, Read JA, Brandon NJ, Nairn AC, Lombroso PJ, Käck H, Ellman JA..  (2017)  X-ray Characterization and Structure-Based Optimization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors.,  60  (22): [PMID:29116812] [10.1021/acs.jmedchem.7b01292]

3. Hou X,Sun JP,Ge L,Liang X,Li K,Zhang Y,Fang H.  (2020)  Inhibition of striatal-enriched protein tyrosine phosphatase by targeting computationally revealed cryptic pockets.,  190  [PMID:32078861] [10.1016/j.ejmech.2020.112131]

Source

Source(1):

• Scientific Literature